- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07950007
ctDNA-Guided Neoadjuvant Therapy in HER2+ Breast Cancer
Individualized Neoadjuvant De-Escalation of T-DXd in HER2+ Breast Cancer (INDEX-HER2)
The convergence of evidence from neoCARHP (comparable pCR between TCHP and THP in an unselected population), DB-11 (activity of T-DXd-THP in high-risk HER2-positive early breast cancer), and I-SPY2 ctDNA data (early ctDNA clearance predicts favorable response and outcomes) provides a strong rationale for biomarker-guided treatment selection. This study uses early on-treatment ctDNA response after standardized THP induction to direct therapy intensity rather than reflexively escalating all patients.
Unlike non-biomarker-selected escalation approaches, this study uses ctDNA as a dynamic biomarker to tailor therapy: patients with early molecular clearance continue THP without carboplatin or ADC exposure, while patients with persistent molecular tumor burden escalate to T-DXd.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Clinical Trials Navigator
- Phone Number: 310-423-2133
- Email: groupcancertrialinformation@cshs.org
Study Locations
-
-
California
-
Beverly Hills, California, United States, 90212
- Cedars-Sinai Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
-
Newly diagnosed, histologically confirmed stage II-III HER2-positive breast cancer (HER2-positive defined per ASCO/CAP guidelines: IHC 3+ or ISH-amplified)
-
No prior systemic therapy for breast cancer
-
Adequate tumor tissue available for molecular profiling and ctDNA assay design
-
Adequate peripheral blood samples obtainable for serial ctDNA testing
-
Age ≥ 18 years
-
ECOG performance status 0-2
-
Adequate organ function as defined by:
- Absolute neutrophil count (ANC) ≥ 1,500/µL
- Platelets ≥ 100,000/µL
- Hemoglobin ≥ 9.0 g/dL
- Total bilirubin ≤ 1.5 × upper limit of normal (ULN)
- AST/ALT ≤ 2.5 × ULN
- Creatinine clearance ≥ 50 mL/min (Cockcroft-Gault)
- Left ventricular ejection fraction (LVEF) ≥ 55% by echocardiogram or MUGA scan
-
Women of childbearing potential must have a negative pregnancy test and agree to use effective contraception during treatment and for the protocol-specified period after the last dose of HER2-directed therapy/T-DXd, per applicable prescribing information and institutional standards.
-
Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.
Exclusion Criteria:
- Distant metastatic disease (Stage IV)
- Prior invasive breast cancer within the past 5 years
- Prior chemotherapy, radiation therapy, or targeted therapy for current breast cancer
- Known hypersensitivity to any component of the treatment regimen, including docetaxel, trastuzumab, pertuzumab, or T-DXd
- Active cardiac disease including: congestive heart failure (NYHA Class II or above), unstable angina, myocardial infarction within 6 months, uncontrolled hypertension, or clinically significant arrhythmia
- Pregnant or breastfeeding
- History of, or current, interstitial lung disease/pneumonitis; active uncontrolled infection requiring systemic therapy
- Any other condition that, in the opinion of the investigator, would make the patient unsuitable for study participation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Single Arm
|
All patients begin with THP for Cycles 1-4. ctDNA is assessed at baseline,C2D1, C5D1, and at the preoperative and postoperative time points. C2D1 ctDNA determines subsequent treatment: ctDNA-negative patients continue THP through C6, while ctDNA-positive patients escalate to T-DXd from C5 through C8 after 4 cycles of THP. A tumor-informed, personalized ctDNA assay will be used. Whole genome sequencing (WGS) will be performed on formalin-fixed paraffin-embedded (FFPE) tumor tissue and matched-normal DNA from buffy coat to identify somatic variants. Based on the WGS results, multiplex PCR primers will be designed for 64 tumor-specific, somatic single-nucleotide variants for each patient. A sample will be considered ctDNA-positive if ≥2 of 64 variants are detected in the circulating cell-free DNA. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
pCR rate in the HR-positive/HER2-positive group
Time Frame: Time of Surgery, up to 24 weeks post on study
|
Pathologic complete response (pCR) is defined as the absence of residual invasive cancer in the breast and regional lymph nodes (ypT0/is ypN0) at the time of surgery following completion of neoadjuvant therapy. |
Time of Surgery, up to 24 weeks post on study
|
|
pCR rate in the HR-negative/HER2-positive group
Time Frame: Time of Surgery, up to 24 weeks post on study
|
Pathologic complete response (pCR) is defined as the absence of residual invasive cancer in the breast and regional lymph nodes (ypT0/is ypN0) at the time of surgery following completion of neoadjuvant therapy. |
Time of Surgery, up to 24 weeks post on study
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
ctDNA Clearance Rate
Time Frame: From enrollment to end of treatment at 8 cycles (24 weeks)
|
Patients who achieve ctDNA clearance during and after neoadjuvant therapy |
From enrollment to end of treatment at 8 cycles (24 weeks)
|
|
Event-Free Survival (EFS)
Time Frame: From time of enrollment until date of documented progression or date of death from any cause, whichever came first, assessed up to 67 months
|
Time from Enrollment to disease progression precluding surgery, local or distant recurrence, or death from any cause |
From time of enrollment until date of documented progression or date of death from any cause, whichever came first, assessed up to 67 months
|
|
Residual Cancer Burden (RCB)
Time Frame: Time of Surgery, up to 24 weeks post on study
|
Proportion of patients achieving RCB-0 or RCB-1 (minimal residual disease) at surgery based on molecular subtypes |
Time of Surgery, up to 24 weeks post on study
|
|
Adverse Events
Time Frame: From enrollment till Time of Surgery, up to 24 weeks post enrollment
|
From enrollment till Time of Surgery, up to 24 weeks post enrollment
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IIT2026-13-Bitar-INDEX-HER2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.